Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma

Exclusion Criteria

• •Subjects meeting any of the following criteria are ineligible:
• •1. Not suitable for standard temozolomide-based chemoradiotherapy
• •2. Prior participation in another interventional clinical trial within 4 weeks before randomization
• •3. Prior implantation of carmustine wafers within 6 months
• •4. Known hypersensitivity to temozolomide or dacarbazine
• •5. Active autoimmune disease or requirement for systemic immunosuppressive therapy
• •6. Active infection including HIV, active hepatitis B or C, or syphilis
• •7. Use of systemic immunosuppressive therapy within 30 days before randomization
• •8. Uncontrolled cardiovascular, metabolic, or systemic disease
• •9. Pregnancy or breastfeeding
• •10. Any condition that, in the investigator's judgment, would interfere with study participation or interpretation of results